Literature DB >> 33918966

Primary Hyperparathyroidism: A Narrative Review of Diagnosis and Medical Management.

Karel Dandurand1, Dalal S Ali1, Aliya A Khan1.   

Abstract

Primary hyperparathyroidism (PHPT) is the most common cause of hypercalcemia in the outpatient setting. Symptomatic presentation includes non-specific signs and symptoms of hypercalcemia, skeletal fragility, nephrolithiasis and nephrocalcinosis. The majority of individuals present at an asymptomatic stage following routine biochemical screening, without any signs or symptoms of calcium or parathyroid hormone (PTH) excess or target organ damage. Indications for surgery have recently been revised as published in recent guidelines and consensus statements. Parathyroidectomy is advised in patients younger than 50 years old and in the presence of either significant hypercalcemia, impaired renal function, renal stones or osteoporosis. Surgery is always appropriate in suitable surgical candidates, however, medical management may be considered in those with mild asymptomatic disease, contraindications to surgery or failed previous surgical intervention. We summarized the optimal medical interventions available in the care of PHPT patients not undergoing parathyroidectomy. Calcium and vitamin D intake should be optimized. Antiresorptive therapy may be used for skeletal protection in patients with an increased fracture risk. Cinacalcet, a calcimimetic agent, has been shown to effectively lower serum calcium and PTH levels. The effect of medical treatment on the reduction in fracture risk is unknown and should be the focus of future research.

Entities:  

Keywords:  bisphosphonates; cinacalcet; denosumab; estrogen; primary hyperparathyroidism; raloxifene

Year:  2021        PMID: 33918966     DOI: 10.3390/jcm10081604

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  3 in total

1.  The Effect of the Frequently Used Cinacalcet for pHPT during the COVID-19 Pandemic on Perioperative Decrease in Parathyroid Hormone.

Authors:  Olga Radulova-Mauersberger; Julia Keßler; Ulrich Keßler; Katrin Stange; Sandra Korn; Jürgen Weitz; Ulrich Bork
Journal:  J Clin Med       Date:  2022-04-04       Impact factor: 4.241

2.  Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience.

Authors:  Julie Bernardor; Sacha Flammier; Jean-Pierre Salles; Cyril Amouroux; Mireille Castanet; Anne Lienhardt; Laetitia Martinerie; Ivan Damgov; Agnès Linglart; Justine Bacchetta
Journal:  Front Pediatr       Date:  2022-08-24       Impact factor: 3.569

3.  Development and validation of a nomogram for risk prediction of nephrolithiasis recurrence in patients with primary hyperparathyroidism.

Authors:  Yihong Zhou; Xi Chu; Dong Jiang; Xiang Wu; Jiarong Xu; Hao Qi; Yuxin Tang; Yingbo Dai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-31       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.